Overview

Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

Status:
Unknown status

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

Summary

This study will treat patients with diffuse large B-cell lymphoma whose disease is in complete remission due to previous treatment with CHOP-R. Half of the patients will receive Zevalin and the other half will receive no further anti-cancer treatment. The two patient groups will be compared to determine if Zevalin given after CHOP-R therapy provides greater benefits than receiving no additional anti-cancer therapy after CHOP R.

Phase:

Phase 3

Details

Lead Sponsor:

CTI BioPharma

Collaborator:

Bayer

Treatments:

Antibodies, Monoclonal